Startup profile · funding coverage
Third Arc Bio funding, valuation and investors
Multifunctional antibodies for oncology and immunology using immune-synapse biology.
Keep track of Third Arc Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A extension
$52M · February 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$52M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Investors in latest funding
Lead: Andreessen Horowitz
Overview
Third Arc Bio develops multifunctional antibodies for oncology and immunology based on immune-synapse biology — aiming for safer, more selective targeting in solid tumors. The company's lead asset ARC101 entered Phase 1 clinical trials. In February 2026, Third Arc announced a $52M Series A extension led by Andreessen Horowitz Bio + Health with Omega Funds and syndicate participation, building on a prior $165M Series A. Third Arc competes in the crowded bispecific and engager space but emphasizes immune-synapse mechanisms for therapeutic window improvement.
Why Third Arc Bio is interesting
Bispecific engagers need safer solid-tumor targeting — a16z led $52M extension atop $165M Series A as ARC101 advances in Phase 1.
Product & use cases
Third Arc discovers and develops multifunctional antibodies — including bispecific engagers — designed via immune-synapse biology for oncology and immunology indications.
- Solid tumor patients in early clinical trials (ARC101 Phase 1)
- Pharma partnerships on engager platforms
- Immunology programs leveraging synapse-targeting science
Key facts
- Series A extension (Feb 2026): $52M led by a16z Bio+Health (company press)
- Prior $165M Series A; lead asset ARC101 in Phase 1
- Multifunctional antibodies for oncology and immunology
- Omega Funds among extension participants
Funding history (newest first)
Series A extension
2026-02 $52MSource: https://www.thirdarcbio.com/news/series-a-extension-2026
Investors in our directory
Funds linked from Third Arc Bio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Immune-synapse biology thesis for selectivity — differentiation unproven clinically but distinct from generic CD3 engagers.
IO engagers face toxicity and efficacy hurdles in solid tumors. Third Arc's extension funding buys Phase 1 readouts — binary clinical risk typical of biotech.
-
Amgen (BiTE platform) incumbent
Established bispecific franchise; commercial scale.
-
Genmab / BioNTech engagers adjacent
Competing solid tumor engager pipelines.
-
Academic IO programs adjacent
Early-stage competing mechanisms.
Notable stories
- Third Arc raised another $52M before Phase 1 data — a16z extension signals confidence in immune-synapse selectivity thesis while ARC101 enters clinic (company press, Feb 2026).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Third Arc Bio's financing or category context.
FAQs about Third Arc Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.